Verzenios ® ▼ (abemaciclib)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: (England, Scotland, Wales) or (Northern Ireland).

Can a Verzenios® ▼ (abemaciclib) patient receive COVID-19 vaccinations?

The use of vaccines against COVID-19 in patients treated with abemaciclib, while not contraindicated, has not been systematically studied.


Warnings and considerations for the concomitant use of COVID-19 vaccines and abemaciclib

The use of vaccines against COVID-19 in patients treated with abemaciclib, while not contraindicated, has not been systematically studied.

Monitor for signs of infections and laboratory anomalies if a patient receives a vaccination before or during the abemaciclib therapy. 

Please consider the risk and benefits of the vaccination on an individual patient basis. 

The following adverse events related to the use of abemaciclib may be important to consider when managing a patient being administered a COVID-19 vaccine or booster while concomitantly being treated with abemaciclib.1 

ILD-Related Warnings and Precautions

Interstitial lung disease (ILD) and/or pneumonitis was reported in patients receiving abemaciclib.

Monitor patients for pulmonary symptoms that could indicate ILD/pneumonitis and treat them as medically appropriate. Symptoms may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. Infectious, neoplastic, and other causes for such symptoms should be excluded by means of appropriate investigations.

Based on the severity of ILD/pneumonitis, abemaciclib may require dose modification.1

Neutropenia-Related Warnings and Precautions

Grade ≥3 neutropenia was reported in patients receiving abemaciclib in breast cancer studies.

Monitor complete blood counts prior to starting abemaciclib therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.

Dose modification is recommended for patients who develop grade 3 or 4 neutropenia.1

Diarrhea-Related Warnings and Precautions

Diarrhea was the most frequently reported treatment-emergent adverse event in patients receiving abemaciclib in clinical studies.

Monitor patients and treat diarrhea reactively rather than routine preventive administration of antidiarrheal medications.

Based on the severity of diarrhea, abemaciclib may require dose modification.1

Infectious Disease Resources for COVID-19 Vaccines

For the most current information regarding COVID-19, please refer to the following resources: 

Additional information and considerations for the use of a SARS-CoV-2 vaccine in patients being treated for cancer is available from ESMO at:


1Verzenios [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2Coronavirus disease (COVID-19) outbreak. World Health Organization Europe. Accessed March 20, 2020.

3COVID-19. European Centre for Disease Prevention and Control. Accessed March 20, 2020.

4European Society for Medical Oncology. Accessed March 23th.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: 28 October 2021

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request